Literature DB >> 19764864

Opportunities in pulmonary valve replacement.

Thomas Oosterhof1, Mark G Hazekamp, Barbara J M Mulder.   

Abstract

Pulmonary regurgitation is the most important residual lesion after initial surgical correction for pulmonary (sub)valvular stenosis in the early life of patients with tetralogy of Fallot or isolated pulmonary stenosis. Symptomatic or asymptomatic patients with severe right ventricular dilatation due to pulmonary regurgitation may benefit from pulmonary valve replacement. Surgery is ideally performed before the right ventricle becomes irreversibly damaged as a result of longstanding volume overload. However, the beneficial effects must be weighed up against the problems associated with degradation of the allograft, which often result in (numerous) reoperations. Owing to the higher risk of thromboembolic events in mechanical prosthesis and the lifetime need for anticoagulation, allografts are the most widely used prosthesis. Degradation of the allograft often leads to reoperation, mostly 10-20 years after initial implantation. For a patient receiving his first allograft at 20 years of age, several reoperations will have to be performed later in life. Percutaneous pulmonary valve implantation has the potential to decrease the number of surgical reoperations.

Entities:  

Mesh:

Year:  2009        PMID: 19764864     DOI: 10.1586/erc.09.89

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  2 in total

1.  Clinical outcomes of transcatheter versus surgical pulmonary valve replacement: a meta-analysis.

Authors:  Ying Zhou; Tixiusi Xiong; Peng Bai; Chong Chu; Nianguo Dong
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

2.  Concomitant Right Ventricular Outflow Tract Cryoablation during Pulmonary Valve Replacement in a Patient with Tetralogy of Fallot.

Authors:  Hong Ju Shin; Seunghwan Song; Yu Rim Shin; Han Ki Park; Young Hwan Park
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2017-02-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.